Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
Data monitoring strategies implemented by our bilingual CRA helped eliminate the backlog to ensure timely database lock in a phase 2 trial for Sanaria's innovative PfSPZ Vaccine for malaria in Equatorial Guinea, an area with limited prior research experience.
Collaborative relationships ensure site sustainability. Keeping a site functional, even in slow times, preserves investment in human and equipment resources and ensures the site is ready to conduct quality research as soon as there is a need.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA